Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridium perfringens toxins are a family of toxic proteins secreted by the bacterium Clostridium perfringens, a Gram-positive anaerobic bacillus responsible for a range of serious diseases in humans and animals. The organism is classified into toxinotypes (A-G) based on its combination of major toxin production, the most significant being alpha (CPA), beta (CPB), epsilon (ETX), iota (ITX), and enterotoxin (CPE), each with distinct pathogenic mechanisms[1][2][4][5]. These toxins act through destroying cell membranes—by phospholipase activity (alpha toxin/CPA), forming pores (beta, epsilon, enterotoxin), or damaging the cytoskeleton (iota toxin), among others. The toxins are key virulence factors, driving diseases such as gas gangrene, necrotizing enteritis, and enterotoxemia, and are highly potent; for example, epsilon toxin is one of the most toxic proteins known. Therapeutic targeting focuses on neutralization or inhibition of toxin activity, with some vaccines developed for veterinary use and antibody-based therapies under research. The term "Clostridium perfringens toxin" is not a single entity but refers to a spectrum of toxins; thus, use of this term may be imprecise unless referring to a specific toxin type[1][2][4]. Caveat: - "Clostridium perfringens toxin" is not a single molecule but refers to a group of toxins. For precise scientific work or therapeutic targeting, the specific toxin should be identified—e.g., "Clostridium perfringens alpha toxin," "Clostridium perfringens beta toxin," etc. The entry is thus considered "is_incorrect: true" in terms of specificity, though there are bona fide protein toxins produced by this bacterium[1][2][4].
Inhibition of toxin binding to host receptors (e.g., anti-toxin antibodies); Inhibition of toxin enzymatic activity (e.g., phospholipase inhibitors for alpha toxin); Blocking pore formation (e.g., synthetic blockers, antibodies); Immunization/vaccination to generate protective immunity
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridium perfringens toxin.